药品专利权的功能异化与修正  

Functional Alienation and Amendment of Drug Patent Right

作　　者：韩成芳 Han Chengfang

机构地区：[1]清华大学法学院

出　　处：《电子知识产权》2021年第2期13-25,共13页Electronics Intellectual Property

基　　金：清华大学自主科研项目“信息社会法治研究”(20205080090)。

摘　　要：高投入、高风险的制药业需要依赖药品专利权激励药品创新并促进药品获得。然而,TRIPs协定下高水平的药品专利保护体系使得药品专利权发生了一系列功能异化,具体表现为减缓药品创新速度、药品获得困难以及国际社会的财富分配不公。因此,有必要反思并重构现有的药品专利国际保护制度,借鉴并创新国际社会诸如公私合作伙伴关系模式与药物研发财税金融支持机制等已有的经验与实践,从而更好地兼顾药品创新与药品持续获得。The high-cost and high-risk pharmaceutical industry relies on drug patents to stimulate drug innovation and promote drug access.However,the high level of drug patent protection under TRIPs has led to a series of functional alienation of drug patent,which include slow pace of drug innovation,diffi culty in obtaining drugs and unfair property distribution in the world.Therefore,it is necessary to rethink and reconstruct th e present international system of drug patent.With the purpose of taking both drug innovation and continuous drug access into account,it’s vital to learn from and even innovate the existin g practice of the international community,such as the public-private partnership model and the fiscal,tax and financial support mechanism for drug research and development.

关 键 词：药品专利权 药品创新 药品获得 

分 类 号：R95[医药卫生—药学]